<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578380</url>
  </required_header>
  <id_info>
    <org_study_id>Prosjektnr 1097.19</org_study_id>
    <nct_id>NCT03578380</nct_id>
  </id_info>
  <brief_title>Supermicrosurgery for Breast Cancer Survivors With Lymphedema.</brief_title>
  <official_title>Supermicrosurgery for Breast Cancer Survivors With Lymphedema. -Prospective Randomized Clinical and Patient-reported Outcomes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset Telemark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised prospective investigation of volume and quality of life results with
      lymphovenous anastomosis in patients with unilateral arm lymphedema after breast cancer using
      Indocyanine Green lymphangiography and MD Anderson Staging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study comparing lymphovenous anastomosis versus conservative
      (compression) treatment for lymphoedema after breast cancer surgery - 50 patients to be
      included in each study arm. The primary endpoint is volume change measured by submersion and
      changes in arm circumference at defined levels from the wrist. Secondary endpoint is health
      related quality of life measured by questionnaire Short Form 36 (SF-36), Hospital Anxiety
      Depression Score (HADS), Fatigue Questionnaire (FQ) and a disease-specific questionnaire,
      Upper Limb Lymphedema score (ULL27).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume</measure>
    <time_frame>12 months</time_frame>
    <description>Volume of arm as described by submersion and circumference measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life ULL27</measure>
    <time_frame>12 months</time_frame>
    <description>To be measured by questionnaire &quot;Upper Limb Lymphedema score 27&quot; (ULL27) by Professor Robert Launois at REES France. The scale measures health related quality of life in patients with upper limb lymphedema.
Construction: 27 questions rated from 1 (lowest quality of life) to 5 highest quality of life.
Dimensions: There are 3 dimensions assessing symptoms, self value, everyday social life. Total score 27-135 Symptom score: 18-90 Self value: 5-25 Social life: 4-20 Question 20 and 22 are part of the self value dimension and are control questions with reverse scores, i.e 1 represents highest quality of life and 5 represents lowest quality of life. The scores for question 20 and 22 are later reversed when adding the total score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Secondary Lymphedema</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphovenous anastomosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conservative treatment with physiotherapy and compression</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Lymphovenous anastomosis</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compression and drainage therapy</intervention_name>
    <description>Treatment with compression stockings and manual drainage (massage therapy)</description>
    <arm_group_label>Compression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral lymphedema of the arm secondary to breast cancer treatment. Stage 1-3
             operable lymphedema.

        Exclusion Criteria:

          -  Frequent or severe cellulitis. All other lymphedema.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Johan Sandberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sykehuset Telemark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Johan Sandberg, MD</last_name>
    <phone>+4735003456</phone>
    <email>johansandberg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sykehuset Telemark</name>
      <address>
        <city>Skien</city>
        <state>Telemark</state>
        <zip>NO-3710</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphovenous bypass</keyword>
  <keyword>Lymphovenous anastomosis</keyword>
  <keyword>Supermicrosurgery</keyword>
  <keyword>Lymphangiography</keyword>
  <keyword>MD Anderson Lymphedema Stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

